key: cord-0310594-y2xfcafi
authors: Eddins, Devon J.; Bassit, Leda; Chandler, Joshua D.; Haddad, Natalie S.; Musall, Katie L.; Yang, Junkai; Kosters, Astrid; Dobosh, Brian S.; Hernández, Mindy R.; Ramonell, Richard P.; Tirouvanziam, Rabindra M.; Lee, F. Eun-Hyung; Zandi, Keivan; Schinazi, Raymond F.; Ghosn, Eliver E.B.
title: Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies
date: 2021-10-24
journal: bioRxiv
DOI: 10.1101/2021.10.22.465481
sha: 83f3981eaadf683442fad488029917abc7e56f6b
doc_id: 310594
cord_uid: y2xfcafi

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from Wuhan, China spurring the Coronavirus Disease-19 (COVID-19) pandemic that has resulted in over 219 million confirmed cases and nearly 4.6 million deaths worldwide. Intensive research efforts ensued to constrain SARS-CoV-2 and reduce COVID-19 disease burden. Due to the severity of this disease, the US Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) recommend that manipulation of active viral cultures of SARS-CoV-2 and respiratory secretions from COVID-19 patients be performed in biosafety level 3 (BSL3) containment laboratories. Therefore, it is imperative to develop viral inactivation procedures that permit samples to be transferred and manipulated at lower containment levels (i.e., BSL2), and maintain the fidelity of downstream assays to expedite the development of medical countermeasures (MCMs). We demonstrate optimal conditions for complete viral inactivation following fixation of infected cells with paraformaldehyde solution or other commonly-used branded reagents for flow cytometry, UVC inactivation in sera and respiratory secretions for protein and antibody detection assays, heat inactivation following cDNA amplification of single-cell emulsions for droplet-based single-cell mRNA sequencing applications, and extraction with an organic solvent for metabolomic studies. Thus, we provide a suite of protocols for viral inactivation of SARS-CoV-2 and COVID-19 patient samples for downstream contemporary immunology assays that facilitate sample transfer to BSL2, providing a conceptual framework for rapid initiation of high-fidelity research as the COVID-19 pandemic continues.

At the end of 2019, a novel betacoronavirus, SARS-CoV-2 (1), emerged from Wuhan in the Hubei 62 province of China causing viral pneumonia that progressed to severe or critical disease in ~20% 63 of infected patients, where in the most critical cases, patients would present with respiratory failure 64 and require mechanical ventilator support in the intensive care unit (2-4). Since then, much 65 research effort has been focused on better understanding pathogenesis and immunity to SARS- 

Though SARS-CoV-2 shares ~80% sequence homology with SARS-CoV (1), it is essential to 78 evaluate efficacy of existing inactivation procedures on novel, independent viral strains. For 79 example, MERS-CoV is also closely related to SARS-CoV but there are notable differences in the 80 inactivation efficacy using gamma-irradiation between the viruses (12, 13). Indeed, there have 81 been earlier reports of efficient viral propagation and inactivation procedures for SARS-CoV-2 82 using heat, fixatives/chemicals/surfactants (e.g., formaldehyde/Trizol ® /Triton X-100), and UVC 83 irradiation (14- 19) , which are comparable to SARS-CoV and MERS-CoV (12, 13, 20-22).

However, though most of these studies highlight efficient and effective viral inactivation protocols 85 (15) (16) (17) (18) (19) , the effect of inactivation on the fidelity of downstream assay readouts and analysis 86 remain largely unknown. Specifically, a detailed report on viral inactivation protocols and how they 87 influence contemporary immunology assays is notably lacking. Contemporary immunological 88 assays including ELISA/Luminex/Mesoscale assays for antibody/protein detection (9, 23-25), 89 metabolomics (26, 27), high-dimensional (Hi-D) flow cytometry (9, 28-30), and multi-omics single- 

To address the need to successfully inactivate virus and permit transfer of material from BSL3 to 94 a lower containment (i.e., BSL2) environment for high-fidelity downstream assays, we examined 95 the efficiency of several viral inactivation methods for contemporary immunological assays 96 including flow cytometry, serology/protein detection, scRNA-seq, and high-throughput 97 metabolomic experiments using both culture-derived virus and infected respiratory samples from 98 COVID-19 patients. Here, we report complete viral inactivation following fixation with 4% PFA or 99 1.6X BD FACS™ Lysis Solution (~2.5% formaldehyde and ~8.3% diethylene glycol) for 30 min at 100 room temperature for flow cytometry, UVC inactivation at ~4,000 µwatts/cm 2 for 30 min in sera 101 and respiratory secretions for protein/antibody detection assays, heat inactivation following first-102 round cDNA amplification of single-cell emulsions for droplet-based scRNA-seq, and metabolite 4 extraction for 30 min with 4 volumes of a 1:1 acetonitrile:methanol solution with 12.5 µM/L D5-104 benzoylhippuric acid at 4˚C for metabolomic studies. These results will serve as conceptual 105 framework and promote rapid initiation of cutting-edge immunology studies as the COVID-19 106 pandemic continues to evolve and for other risk group 3 agents that require higher containment. Protein" (document number CG000208; 10X Genomics) targeting 20,000 and 10,000 cells,

respectively. An aliquot of the emulsion was collected following encapsulation for analysis by 232 plaque assay. The remaining emulsion was processed for cDNA synthesis reaction following the 233 manufacturer's protocol with reagent volumes adjusted to reflect the reduced reaction volume 234 after taking aliquots for plaque assays. Polymerase chain reaction (PCR) amplification profile was 7 45 min at 53˚C followed by 5 min at 85˚C. An additional aliquot of the cDNA suspension was 236 collected following PCR reactions and either plated immediately or frozen at -80˚C for analysis by 237 plaque assay. Plaque assays were also performed on the encapsulation emulsion alone (without 238 including virus-infected cells) to evaluate reagent cytotoxicity on Vero E6 monolayers. 

To determine PFU equivalents (ePFU) from respiratory samples, vRNA was extracted from 10-312 fold serial dilutions of stock SCV2-WA1 of a known titer for RT-qPCR to generate a standard 313 curve from which number of genome copies per PFU could be extrapolated as previously 

To evaluate the ability of commonly-used fixatives in flow cytometry (here, formaldehyde-based 321 and PFA) to completely inactivate SARS-CoV-2-infected cells for transfer to lower containment 9 settings, we performed a time-course of inactivation (Fig. 1A) using 2% and 4% PFA (diluted from 323 a 20% stock, see methods) along with 1.6X BD FACS™ Lysis Solution (10X stock diluted 1:6 in 324 sterile dH2O). Cells exposed to 2% and 4% PFA for 15 min at room temperature were still able to 325 produce infectious virus when returned to culture for 48 h (Fig. 1B,C) , with a decrease in viral titer 326 (PFU/mL). This is in contrast to a previous report that indicated 10 min treatment with 4% PFA is 327 sufficient to inactivate virus (14). However, infectious virus was not detected by plaque assay 328 following 15 min exposure to 1.6X BD FACS™ lysis solution and at all subsequent time points 329 (Fig. 1B,C) . Cells treated with 4% PFA for 30 min at RT were no longer infectious, however, 60 330 min was required to fully inactivate virus in cells treated with 2% PFA at RT. These data indicate 331 that common fixation protocols (30 min fixation at RT) for commercially-available fixatives, 332 specifically those with ≥4% PFA, are sufficient for inactivating SARS-CoV-2 infected cells. 

First, we determined viral load in the respiratory secretions by extrapolating ePFU/mL from RT-343 qPCR results of respiratory secretions (see methods) (44). Using a standard curve generated 344 from virus stock of a known titer ( Fig. 2A) , we determined 1 PFU to be equivalent to 73 SARS-

CoV-2 genome copies in RT-qPCR data. This allowed for more accurate viral detection and 346 quantification (Fig. 2B ) since endotracheal aspirate (ETA) and bronchoalveolar lavage fluid 347 (BALF) samples are standard modalities used to diagnose ventilator-associated pneumonia (45, 348 46) and can be inundated with pulmonary microbes that grow in cultures, confounding traditional 349 plaque assays (see Fig. S1 ). As expected from our previous study (9), we found that viral load 350 varied across patient groups where those with severe disease had lower (or absent) viral load at 351 time of sampling (samples were combined with our previously data (9); Fig. 2B ). Following 30 min 352 exposure to UVC-irradiation, both virus stock (2.1 x 10 5 PFU/mL), and respiratory secretions were 353 not detected by plaque assay (Fig. 3C) , indicating complete viral inactivation. Additionally, we 354 demonstrate that UVC-inactivation abolishes microbial growth in plaque assays that hampered 355 accurate viral load detection in ETA samples (Fig. S1) , which is consistent with established 356 efficacy of UVC-inactivation for a diverse range of pathogenic microbes (47, 48).

To determine the effect of 30 min exposure to UVC-irradiation on protein/antibody detection, we 360 compared untreated and UVC-treated plasma samples from both mild and severe COVID-19 361 patients (Fig. 2D) . We did not observe any significant differences in the levels of anti-SARS-CoV- To determine optimal inactivation procedure for metabolomics, we first evaluated the effects of 370 UVC-inactivation described above on Standard Reference Material 1950 of metabolites in human 371 plasma (49). UVC-inactivation significantly altered the metabolic profile of samples (Fig. 3A) . We

show that the differentially-expressed metabolites between untreated and UVC-treated plasma 373 samples are redox active metabolites (Fig. 3B) , suggesting that reactive oxygen species (ROS) 374 known to be produced during UVC irradiation (50) lead to sample oxidation during this procedure 375 similar to ROS oxidation in vivo (51-53). Therefore, UVC-inactivation is not suitable for 376 metabolomic studies, especially if interrogating redox active metabolites. 

We next evaluated the efficacy of viral inactivation following single-cell encapsulation (which 404 contains a proprietary lysis solution) of SCV2-WA1-infected (MOI 0.04) Vero E6 or Calu-3 cells.

We show that the standard single-cell encapsulation step alone is not sufficient to fully inactivate 406 SARS-CoV-2, which could be detected in subsequent plaque assays (Fig. 4A,B) . Therefore, we 407 tested the efficacy of the first round cDNA synthesis reaction, which includes exposure to 408 temperatures ≥53˚C, in viral inactivation. We show that after the PCR reaction (45 min at 53˚C 409 followed by 5 min at 85˚C), infectious SARS-CoV-2 was not detectable by plaque assay (Fig.   410 11 4A,B) . Taken together, our data demonstrate that scRNA-seq emulsions of SARS-CoV-2-infected 411 cells are fully inactivated only after heat inactivation following the cDNA synthesis reaction using 412 the conditions described in the manufacturer's protocol (45 min at 53˚C followed by 5 min at 85˚C), 413 which can then be transferred to lower containment for library preparation and sequencing.

Indeed, after sequencing, we find >2.3 million viral transcripts (or unique molecular identifiers; 415 UMI) in ~8,000 SCV2-WA1-infected Calu-3 cells (Fig. 4C) .

To date, there have been multiple studies to evaluate efficacy of viral inactivation procedures 

Since its induction in the 1960s, flow cytometry has been the preeminent technology for single- 

Similarly, we show that UVC irradiation (~4000 µwatts/cm 2 ) for 30 min is sufficient to fully 444 inactivate high titer SCV2-WA1 viral stocks and respiratory supernatants from patients with 445 minimal effects on protein/antibody detection (59), which will promote further studies on 446 secretions from ETA and/or BALF to better understand local versus systemic responses (9, 25).

It is important to note that a previous study on UVC-inactivation of SARS-CoV found BSA to 448 protect virus from UVC-inactivation even after 60 min exposure (20). Therefore, we avoided BSA 449 in solutions used in respiratory sample preparation (9), and plasma samples were inactivated 450 prior to dilution in the Luminex proteomic assay buffer (1% BSA in 1X PBS, see methods).

Despite having negligible effects in the proteomic assays, we did observe that UVC inactivation 453 significantly altered metabolomic profiles is human plasma samples. Specifically, we show that 12 redox active metabolites such as methionine and urate are oxidized following UVC inactivation, 455 significantly increasing signals for methionine sulfoxide and allantoin, respectively (51, 52).

Similarly, bilirubin, which is oxidized to biliverdin, is significantly decreased with UVC treatment 457 (53). Therefore, UVC-inactivation of clinical samples could lead to misleading biological 458 interpretations, artificially skewing sample metabolites to a more oxidized profile (51-53).

However, high concentration methanol (≥80%) (60, 61) and methanol/acetone mixtures (13, 22) 460 have previously been shown to successfully inactivate many viral infected samples including 461 SARS- CoV-2 (17-19) . The extraction solvent we used is similar to that used in many metabolomic 462 sample preparation techniques, and was sufficient to inactivate virus while maintaining data 463 integrity.

Systems immunology approaches, including multi-omic scRNA-seq, have greatly advanced our 466 understanding of COVID-19 immunity and pathogenesis (9, 31, 32). However, a detailed report 467 on inactivation efficacy of scRNA-seq pipelines is notably lacking. We demonstrate that in the 468 standard 10X Genomics pipeline, encapsulation alone was insufficient to fully inactivate virus.

According to the manufacturer's guidelines, a cDNA synthesis reaction is the next immediate step 

The 531 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and 532 naming it SARS-CoV-2. Nat Microbiol

Clinical features of patients infected 534 with 2019 novel coronavirus in Wuhan

Pathological inflammation in patients with COVID-19: a key role for 536 monocytes and macrophages

Risk Factors Associated With Acute 538 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

The first 12 months of COVID-19: a timeline of 541 immunological insights

SARS and MERS: recent insights 543 into emerging coronaviruses

A decade after SARS: strategies for controlling 545 emerging coronaviruses

SARS-CoV-2 variants, spike mutations and immune escape

Pathogenic 550 neutrophilia drives acute respiratory distress syndrome in severe COVID-19 patients. bioRxiv

Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region -United 554

Ethnic Disparities in COVID-19 Incidence by Age, Sex, and Period Among Persons Aged <25

Inactivation of the coronavirus that 560 induces severe acute respiratory syndrome, SARS-CoV

Inactivation 563 and safety testing of Middle East Respiratory Syndrome Coronavirus

Growth, detection, quantification, 566 and inactivation of SARS-CoV-2

CoV-2 with deep-UV LED irradiation

CoV-2. Viruses

Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays

Analysis of inactivation of SARS-CoV-2 by specimen transport media, nucleic acid extraction 576 reagents, detergents, and fixatives

Evaluation 578 of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings

Evaluation of inactivation methods for severe acute respiratory 581 syndrome coronavirus in noncellular blood products

Inactivation of SARS coronavirus by means of povidone-585 iodine, physical conditions and chemical reagents

Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic 589 Liquefaction of Respiratory Samples from COVID-19 Patients

One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses

IgA dominates the early 595 neutralizing antibody response to SARS-CoV-2

Insights gained into respiratory infection pathogenesis using 597 lung tissue metabolomics

Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host 600 Microbe

Development, application and computational analysis of high-dimensional fluorescent antibody 603 panels for single-cell flow cytometry

High-605 dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of 606 granulocytes in COVID-19

Deep 608 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic 609 implications

Single-cell multi-omics analysis of the immune response in COVID-19

Disease-State Shift between Mild and Moderate COVID-19

Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. Microorganisms

Tabellen zur näherungsweisen Bestimmung von Titern

A simple method of estimating fifty per cent endpoints. American 621 journal of epidemiology

Determination of 50% endpoint titer using a simple formula

Antiviral activities and 625 cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues

Quantitative analysis of dose-effect relationships: the combined 628 effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation

Adaptive linear step-up procedures that control the 630 false discovery rate

STAR: ultrafast 632 universal RNA-seq aligner

The Architecture of SARS-CoV-2

Genomic characterisation and 638 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The 639 lancet

Comparison of a real-time reverse transcriptase PCR assay and a culture technique for 642 quantitative assessment of viral load in children naturally infected with respiratory syncytial 643 virus

Endotracheal aspiration in the diagnosis of ventilator-associated 645 pneumonia

Endotracheal aspirate and bronchoalveolar lavage fluid analysis: interchangeable diagnostic 648 modalities in suspected ventilator-associated pneumonia?

Efficient inactivation of viruses 651 and mycoplasma in animal sera using UVC irradiation

Potential and limitation of UVC irradiation for the inactivation of pathogens in 654 platelet concentrates

Metabolite profiling of a NIST Standard Reference Material for human plasma

NMR, and clinical laboratory analyses, libraries, and web-based resources

Du Plessis SS. Ultraviolet Light Induced Generation of 660

Reactive Oxygen Species

Allantoin in 662 human plasma, serum, and nasal-lining fluids as a biomarker of oxidative stress: avoiding 663 artifacts and establishing real in vivo concentrations

The biological significance of methionine sulfoxide 666 stereochemistry. Free Radic Biol Med

Limited role for the bilirubin-668 biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase

Cytometry: today's technology and tomorrow's 671 horizons

Seventeen-colour flow cytometry: 673 unravelling the immune system

8 color, 10-675 parameter flow cytometry to elucidate complex leukocyte heterogeneity

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-679

Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Virus 684 inactivation and protein recovery in a novel ultraviolet-C reactor

Inactivating Zaire Ebolavirus in Whole-Blood Thin Smears Used for Malaria Diagnosis

Establish a standard inactivation protocol for virus 690 research in a high containment laboratory

Figure 1. Fixation with commercially-available fixatives promote complete inactivation of 698 SARS-CoV-2-infected cells amenable to flow cytometric analyses

Schematic of inactivation time course performed to evaluate inactivation efficiency. SNT 700 = supernatant

Representative plaque assays from inactivation time course

Quantification of viral load for the 4 fixatives across the 4 time-points evaluated. ND = Not 703 Detected

Viral curve generated from serially-diluted SCV2-WA1 stock of a known titer to extrapolate 711 ePFU/mL from RT-qPCR data

Viral load (ePFU/mL) in respiratory supernatant (Resp. SNT) from non-induced sputum 713 (healthy and mild) and endotracheal aspirates (ETA; severe) samples using the viral curve 714 generated in A. Dotted line = lower limit of quantification for the ePFU conversion 715 determined by lowest dilution of stock virus (10 -6 ) detected by RT-qPCR

Representative plaque assays from stock SCV2-WA1 virus and respiratory supernatant 718 (Resp. SNT) samples and quantification of viral load (PFU/mL for SCV2-WA1 stock and 719 ePFU/mL for Resp. SNT from B) before and after UVC-treatment

ND = Not Detected (by plaque assay)

Comparison of SARS-CoV-2 antibody measurements in untreated and UVC-treated 722 plasma samples from mild and severe COVID-19 patients

Metabolite extraction solvent (Solution A) completely inactivates SARS-CoV-2 727 and maintains sample quality for downstream metabolomics assays

Volcano plot (FDR <10%) displaying differentially-expressed metabolites in untreated 729 versus UVC-treated NIST (standard) plasma samples

Example plots of 3 representatives differentially-expressed, redox-active metabolites in 731 untreated vs. UVC-treated NIST plasma samples

FRNA results evaluating inactivation of the metabolite extraction solvent (Solution A) in 733 the standard metabolomic sample processing procedure (see methods) and Triton X-100

Heat inactivation during cDNA synthesis completely inactivates SARS-CoV-2 in 737 scRNA-seq emulsions

Representative plaque assays performed using 10X Genomics' emulsion reagents alone 739 (without cells) to evaluate reagent cytotoxicity on Vero E6 cells and single-cell emulsion 740 with SCV2-WA1-infected Vero E6 cells (MOI 0.04), and the same emulsion after cDNA 741 synthesis PCR reaction

Quantification of viral load in single-cell emulsions of SCV2-WA1-infected Calu-3 cells 743 (MOI 0.04) immediately after encapsulation and following PCR reaction for cDNA 744 synthesis. N=3 independent samples

UMAP visualization of scRNA-seq data from SCV2-WA1

746 N=8061 cells) showing expression of the 12 SARS-CoV-2 genes and total viral UMIs

UVC inactivation abolishes microbial growth in plaque assay cultures

Representative image of plaque assay cultures for respiratory supernatant samples (severe 753

COVID-19 patients) before and after UVC-treatment (30 min at ~4000 µwatt/cm 2 ). Yellow arrows 754 indicate microbial growth

This work was supported by funds from NIH/NIAID R01AI123126 (EEBG) and R01AI123126-